Pharmaceuticals, Biotechnology & Life Sciences

Discover how Annovis Bio is advancing neurodegenerative treatments, focusing on rare Alzheimer’s and Parkinson’s cases while navigating biotech challenges.

Corvus Pharmaceuticals’ newly approved immune‑targeting cancer drug is now widely available in U.S. pharmacies, boosting patient access and provider confidence while positioning the biotech firm for future growth.

Biomea Fusion, Inc. pioneers irreversible small‑molecule drugs for genetically defined cancers—explore its precision‑medicine strategy, market potential, and investor outlook.

Valbiotis SA: exploring nutrition‑based cardiometabolic solutions amid price volatility—why investors are watching its biotech gamble.

Explore how Iovance Biotherapeutics gains a strategic edge in advanced melanoma after Replimune’s regulatory setback—insight into its TIL‑focused immunotherapy and market impact.

Cogent Biosciences’ latest stake‑buying move may reshape biotech competition, impacting its stock volatility and future growth prospects.

ADMA Biologics’ share plunge follows a short‑seller report alleging financial misconduct. Explore how regulatory scrutiny, investor sentiment, and its plasma‑derived therapies could shape a future rebound.

AbCellera Biologics drives antibody discovery with cutting‑edge genomics, microfluidics & AI, boosting investor confidence and setting the stage for key 2026 data releases.

Bas­ilea Pharmaceutica’s strong governance, investor approval and focus on anti‑infective therapies make it a resilient biotech play poised for future growth.

Virbac’s Q1 2026 revenue up 7.7% as Supercharge4 drives double‑digit growth in the booming global dewormer market.